Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis

Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

(2011) Anette Chrusciak-Talhari et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Antimony-Resistant Clinical Isolates of Leishmania donovani Are Susceptible to Paromomycin and Sitamaquine

(2011) Arpita Kulshrestha et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis

(2011) V. Ramesh et al.   BRITISH JOURNAL OF DERMATOLOGY

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance

(2011) T. Downing et al.   GENOME RESEARCH

Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania braziliensis Refractory to the Drug

(2009) M. P. Sanchez-Canete et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Susceptibility of Field Isolates of Leishmania donovani to Miltefosine and Amphotericin B: Correlation with Sodium Antimony Gluconate Susceptibility and Implications for Treatment in Areas of Endemicity

(2008) D. Kumar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients

(2007) Jesús Troya et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES